Skip to main content
OpenTrials

Clinical trial condition

LGMDR16 - DAG1 Related Dystroglycanopathy (Formerly LGMD2P)

Explore clinical trials studying LGMDR16 - DAG1 Related Dystroglycanopathy (Formerly LGMD2P). Study availability and eligibility vary by location and protocol.

1 public trial 1 recruiting study
Refine in advanced search Browse all conditions

LGMDR16 - DAG1 Related Dystroglycanopathy (Formerly LGMD2P) trial results

Recruiting

Congenital Muscle Disease Study of Patient and Family Reported Medical Information

NCT01403402

Conditions
Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Fatty Liver and Infantile-onset Cataract Caused by TRAPPC11 Mutations), Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Hypoglycosylation of Dystroglycan and Epilepsy), Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Hypoglycosylation of Dystroglycan), +89 more
Locations
  • Congenital Muscle Disease International Registry (www.cmdir.org) Lakewood, California, United States
View Trial Details

Related conditions